
Göran Engberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7975433/publications.pdf Version: 2024-02-01



CöDAN ENCREPC

#	Article	IF	CITATIONS
1	Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia. Molecular Psychiatry, 2022, 27, 3247-3261.	7.9	9
2	Identification of cerebrospinal fluid and serum metabolomic biomarkers in first episode psychosis patients. Translational Psychiatry, 2022, 12, .	4.8	6
3	Blockade of KAT II Facilitates LTP in Kynurenine 3-Monooxygenase Depleted Mice. International Journal of Tryptophan Research, 2021, 14, 117864692110413.	2.3	5
4	GRK3 deficiency elicits brain immune activation and psychosis. Molecular Psychiatry, 2021, 26, 6820-6832.	7.9	12
5	Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 933-938.	3.2	4
6	Torgny Svensson, a superb mind and an inspiring colleague. International Journal of Neuropsychopharmacology, 2020, 23, 543-544.	2.1	0
7	Repeated administration of LPS exaggerates amphetamine-induced locomotor response and causes learning deficits in mice. Journal of Neuroimmunology, 2020, 349, 577401.	2.3	8
8	CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. IBRO Reports, 2020, 8, 136-142.	0.3	5
9	Peripheral and central levels of kynurenic acid in bipolar disorder subjects and healthy controls. Translational Psychiatry, 2019, 9, 37.	4.8	51
10	Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis. Schizophrenia Research, 2019, 208, 490-492.	2.0	5
11	Lipopolysaccharide Increases Cortical Kynurenic Acid and Deficits in Reference Memory in Mice. International Journal of Tryptophan Research, 2019, 12, 117864691989116.	2.3	8
12	Increased peripheral levels of TARC/CCL17 in first episode psychosis patients. Schizophrenia Research, 2019, 210, 221-227.	2.0	8
13	Pharmacological Treatment in Forensic Psychiatry—A Systematic Review. Frontiers in Psychiatry, 2019, 10, 963.	2.6	17
14	Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients. Schizophrenia Research, 2018, 199, 438-441.	2.0	8
15	CSF GABA is reduced in first-episode psychosis and associates to symptom severity. Molecular Psychiatry, 2018, 23, 1244-1250.	7.9	44
16	First-episode psychosis patients display increased plasma IL-18 that correlates with cognitive dysfunction. Schizophrenia Research, 2018, 195, 406-408.	2.0	15
17	Increased number of monocytes and plasma levels of <scp>MCP</scp> â€1 and <scp>YKL</scp> â€40 in firstâ€episode psychosis. Acta Psychiatrica Scandinavica, 2018, 138, 432-440.	4.5	20
18	Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia. Neuropharmacology, 2018, 138, 130-139.	4.1	25

GöRAN ENGBERG

#	Article	IF	CITATIONS
19	The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology, 2017, 112, 297-306.	4.1	187
20	Decreased levels of kynurenic acid in prefrontal cortex in a genetic animal model of depression. Acta Neuropsychiatrica, 2017, 29, 54-58.	2.1	13
21	LPS-induced cortical kynurenic acid and neurogranin-NFAT signaling is associated with deficits in stimulus processing during Pavlovian conditioning. Journal of Neuroimmunology, 2017, 313, 1-9.	2.3	12
22	Kynurenic acid and psychotic symptoms and personality traits in twins with psychiatric morbidity. Psychiatry Research, 2017, 247, 105-112.	3.3	18
23	Cerebrospinal fluid kynurenine and kynurenic acid concentrations are associated with coma duration and long-term neurocognitive impairment in Ugandan children with cerebral malaria. Malaria Journal, 2017, 16, 303.	2.3	29
24	Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice. Neurochemical Research, 2016, 41, 2243-2255.	3.3	27
25	Inhibition of kynurenine aminotransferase II reduces activity of midbrain dopamine neurons. Neuropharmacology, 2016, 102, 42-47.	4.1	33
26	A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Molecular Psychiatry, 2016, 21, 1342-1350.	7.9	71
27	Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms. Brain, Behavior, and Immunity, 2016, 51, 47-55.	4.1	56
28	Chronic Antipsychotic Treatment in the Rat – Effects on Brain Interleukin-8 and Kynurenic Acid. International Journal of Tryptophan Research, 2015, 8, IJTR.S25915.	2.3	15
29	Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia — significance for activation of the kynurenine pathway. Journal of Psychiatry and Neuroscience, 2015, 40, 126-133.	2.4	173
30	The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Molecular Psychiatry, 2014, 19, 334-341.	7.9	91
31	Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment – Role of brain kynurenic acid. Brain, Behavior, and Immunity, 2014, 36, 80-89.	4.1	37
32	Imbalanced Kynurenine Pathway in Schizophrenia. International Journal of Tryptophan Research, 2014, 7, IJTR.S16800.	2.3	95
33	Sustained Elevation of Kynurenic Acid in the Cerebrospinal Fluid of Patients with Herpes Simplex Virus Type 1 Encephalitis. International Journal of Tryptophan Research, 2013, 6, IJTR.S13256.	2.3	17
34	Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia. Schizophrenia Bulletin, 2012, 38, 426-432.	4.3	248
35	Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. Journal of Psychiatry and Neuroscience, 2012, 37, 53-57.	2.4	65
36	Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disorders, 2012, 14, 719-726.	1.9	70

GöRAN ENGBERG

#	Article	IF	CITATIONS
37	Kynurenine 3-monooxygenase (KMO) polymorphisms in schizophrenia: An association study. Schizophrenia Research, 2011, 127, 270-272.	2.0	19
38	Elevation of cerebrospinal fluid interleukin-1β in bipolar disorder. Journal of Psychiatry and Neuroscience, 2011, 36, 114-118.	2.4	151
39	Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. Journal of Psychiatry and Neuroscience, 2010, 35, 195-199.	2.4	87
40	Activation of brain interleukin- $1\hat{l}^2$ in schizophrenia. Molecular Psychiatry, 2009, 14, 1069-1071.	7.9	147
41	Pharmacological Manipulation of Kynurenic Acid. CNS Drugs, 2009, 23, 91-101.	5.9	138
42	Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. International Journal of Neuropsychopharmacology, 2009, 12, 501.	2.1	47
43	Induction of the kynurenine pathway by neurotropic influenza a virus infection. Journal of Neuroscience Research, 2008, 86, 3674-3683.	2.9	40
44	Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sciences, 2008, 83, 170-175.	4.3	74
45	The kynurenic acid hypothesis of schizophrenia. Physiology and Behavior, 2007, 92, 203-209.	2.1	148
46	Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: A pharmacological analysis. Neuropharmacology, 2007, 53, 918-924.	4.1	42
47	Cerebrospinal fluid kynurenic acid in male and female controls – Correlation with monoamine metabolites and influences of confounding factors. Journal of Psychiatric Research, 2007, 41, 144-151.	3.1	31
48	Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons—Possible involvement of endogenous kynurenic acid. Synapse, 2006, 59, 290-298.	1.2	58
49	Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophrenia Research, 2005, 80, 315-322.	2.0	214
50	Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse, 2004, 52, 114-122.	1.2	60
51	Kynurenic Acid And Schizophrenia. Advances in Experimental Medicine and Biology, 2003, 527, 155-165.	1.6	65
52	GABA B receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 173-180.	3.0	101
53	Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiologica Scandinavica, 2002, 175, 45-53.	2.2	73
54	Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neuroscience Letters, 2001, 313, 96-98.	2.1	411

Göran Engberg

#	Article	IF	CITATIONS
55	Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids, 2001, 20, 353-362.	2.7	60
56	Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: A new metabolic pathway?. Synapse, 2001, 40, 294-301.	1.2	47
57	Nicotine-induced excitation of locus coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid. Synapse, 2000, 37, 104-108.	1.2	32
58	Inhibition of glucose-induced insulin secretion by a peripheral-type benzodiazepine receptor ligand (PK) Tj ETQqC	0 0 rgBT 3.0	/Overlock 10 ⁻
59	Nicotineâ€induced excitation of locus coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid. Synapse, 2000, 37, 104-108.	1.2	1
60	Inhibition of firing rate and changes in the firing pattern of nigral dopamine neurons by Î ³ -hydroxybutyric acid (GHBA) are specifically induced by activation of GABAB receptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357, 611-619.	3.0	59

61	Inhibition of dopamine re-uptake: Significance for nigral dopamine neuron activity. , 1997, 25, 215-226.		20
62	Inhibition of dopamine reâ€uptake: Significance for nigral dopamine neuron activity. Synapse, 1997, 25, 215-226.	1.2	1
63	GABAB-Receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra. Synapse, 1993, 15, 229-238.	1.2	94